Effects of DaxibotulinumtoxinA for Blepharospasm and Hemifacial Spasm
A legfontosabb adatok
- Hol
- The Bronx (Egyesült Államok)A helyszín megnézése
- Fázis
- 4. fázis
Helyszínek itt: Egyesült Államok
- Montefiore Medical CenterThe Bronx, Egyesült ÁllamokContact: Anne Barmettler, MDRésztvevőt keres
Kérdések a vizsgálat csapatának
- Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
- Megtérítik az utazási költséget?
- Megtarthatom a saját orvosomat?
- Mi történik, ha ki akarok lépni?
Contact the study team: see the registry record → Contacts and Locations
Oldal nyomtatása az orvosomnakA vizsgálat adatai
- Ki végzi
- Montefiore Medical Center
- Azonosító
- NCT06195241
- A regiszteradat frissítve
- 2026. április 23.
- Eredeti leírás
The goal of this clinical trial is to test the effects of DaxibotulinumtoxinA-Lanm (Daxxify) in patients with benign essential blepharospasms (BEB) and hemifacial spasms (HFS). The main questions to answer:A teljes eredeti leírásKevesebb
The Safety and Efficacy of DaxibotulinumtoxinA-Lanm for Benign Essential Blepharospasm and Hemifacial Spasm
The goal of this clinical trial is to test the effects of DaxibotulinumtoxinA-Lanm (Daxxify) in patients with benign essential blepharospasms (BEB) and hemifacial spasms (HFS). The main questions to answer:
1. Is there clinically significant difference (measured by Jankovic Rating Scale (JRS) score from base to peak efficacy) for patients with BEB and HFS treated with Daxxify? 2. What percentage of patients achieve a clinical response?
Participants historically treated with Botox for either BEB or HFS will be crossed over to Daxxify treatment in order to serve as their own control and examine the efficacy of Daxxify.
Bevonási feltételek: Benign essential blepharospasm (BEB) or hemifacial spasm (HFS) as diagnosed by an ophthalmologist; No known neurologic or neuromuscular systematic medications; No history or surgical intervention for BEB or HFS; Patients are required to have a minimum score of 4 out of 8 on the modified Jankovic Rating Scale for Severity/Frequency.
Kizáró feltételek: Patients will be excluded if age < 18, are pregnant, are non-willing, or have contra-indications to botulinum toxin.